The $800 Million Pill: The Truth behind the Cost of New Drugs / Edition 1

The $800 Million Pill: The Truth behind the Cost of New Drugs / Edition 1

by Merrill Goozner
     
 

"Why do life-saving prescription drugs cost so much? Drug companies insist that prices merely reflect the millions they invest in research and development. In this expose, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government funded research and again by paying astronomically high prices for prescription… See more details below

Overview

"Why do life-saving prescription drugs cost so much? Drug companies insist that prices merely reflect the millions they invest in research and development. In this expose, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates that almost all the important and life-saving new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the innovative work is over, the pharmaceutical industry often steps in to reap the profit." "Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms, whose bottom line often takes precedence over the advance of medicine. Stories of a university biochemist who spent twenty years searching for single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible - these accounts illustrate how medical breakthroughs actually take place." The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private-sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.

Read More

Product Details

ISBN-13:
9780520246706
Publisher:
University of California Press
Publication date:
10/10/2005
Edition description:
New Edition
Pages:
303
Sales rank:
1,429,059
Product dimensions:
6.00(w) x 9.00(h) x 0.88(d)

Table of Contents

Why do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping expose, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates that almost all the important new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the innovative work is over, the pharmaceutical industry often steps in to reap the profit.

Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms whose bottom line often takes precedence over the advance of medicine. A university biochemist who spent twenty years searching for a single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible--these engrossing accounts illustrate how medical breakthroughs actually take place.

The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, Goozner insists. This book is essential reading for everyone concerned about the politicallycharged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >